Please login to the form below

Not currently logged in
Email:
Password:

obeticholic acid

This page shows the latest obeticholic acid news and features for those working in and with pharma, biotech and healthcare.

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Intercept builds its case for Ocaliva in NASH, but safety still an issue

taking Ocaliva (obeticholic acid), which is vying to become the first drug to be approved for the fatty liver disease.

Latest news

  • Genfit launches $135m IPO to back NASH plans Genfit launches $135m IPO to back NASH plans

    There are no approved therapies at the moment, but several candidates are coming through late-stage development, including Intercept’s obeticholic acid which is being prepared for a US filing later

  • Liver specialist Genfit files $120m IPO on Nasdaq Liver specialist Genfit files $120m IPO on Nasdaq

    Shortly afterwards, Intercept Pharma reported somewhat mixed phase 3 data for its NASH drug obeticholic acid, although analysts suggested the data could still be enough to support an FDA approval.

  • Intercept NASH drug closes in on FDA approval Intercept NASH drug closes in on FDA approval

    Shares in Intercept rose almost 20% on the Nasdaq immediately after the results of the phase 3 REGENERATE trial of obeticholic acid were announced, but dipped back to close up 6%. ... The trial isn’t a home run, however. Neither dose of obeticholic

  • Better together when buying medicines? Taking stock of the BeNeLuxA initiative Better together when buying medicines? Taking stock of the BeNeLuxA initiative

    was subsequently updated) for Vertex’s cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor), Intercept’s Ocaliva (obeticholic acid) for primary biliary cholangitis and for Biogen’s Spinraza (nusinersen) for spinal muscular atrophy

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    Among these, Intercept’s Ocaliva (obeticholic acid) is already approved to treat rare liver disease primary biliary cirrhosis, and is in phase 3 for NASH patients with cirrhosis, while Gilead Sciences

More from news
Approximately 5 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics